Het traject van vasculaire biologie naar de kliniek: inflammatie verminderen verlaagt het CV risico

Inflammation expert opinions

20 sep. 2017

Video navigatie menu

  • CV event reduction as a consequence of lowering inflammation: top-line results of the CANTOS-trial 0:38
  • The beginning of vascular biology research on the inflammation hypothesis 1:10
  • Translation of experimental research into clinical application 3:10
  • What are the potential adverse effects of inhibiting IL-1β and how might they be mitigated? 5:15
  • 'Adverse events' in the CANTOS trial also include favorable side-effects 6:19
  • Considering the CANTOS results, where should we go from here? 7:15

Educatieve informatie

Deze video werd geproduceerd als een educatieve service door PACE-CME met als doel om een expert perspectief te geven op nieuwe ontwikkelingen zoals de presentatie van de CANTOS studie (The Canakinumab Anti-inflammatory Thrombosis Outcomes Study). Bezoek ook voor meer informatie en andere internationale expert opinions ook


Prof. Paul Ridker - is director of the Center for Cardiovascular Disease Prevention, a translational research unit at Brigham and Women’s Hospital. A cardiovascular medicine specialist, and Eugene Braunwald Professor of Medicine at Harvard School of Medicine.

Prof. Peter Libby - is Senior Advisor, Center for Interdisciplinary Cardiovascular Sciences; Mallinckrodt Professor of Medicine, Harvard Medical School; Senior Physician, Brigham and Women's Hospital, Boston, MA, USA


Funding to produce this video was provided by an unrestricted educational grant from Novartis.